RT Journal Article
SR Electronic
T1 Safety and immunogenicity of VLPCOV-02, a SARS-CoV-2 self-amplifying RNA vaccine with a modified base, 5-methylcytosine, in healthy individuals
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.09.04.23294493
DO 10.1101/2023.09.04.23294493
A1 Aboshi, Masayuki
A1 Matsuda, Kenta
A1 Kawakami, Daisuke
A1 Kono, Kaoru
A1 Kazami, Yoko
A1 Sekida, Takashi
A1 Komori, Mai
A1 Morey, Amber L.
A1 Suga, Shigeru
A1 Smith, Jonathan F.
A1 Fukuhara, Takasuke
A1 Iwatani, Yasumasa
A1 Yamamoto, Takuya
A1 Sato, Nobuaki
A1 Akahata, Wataru
YR 2023
UL http://medrxiv.org/content/early/2023/09/06/2023.09.04.23294493.abstract
AB Continuing emergence of variants of concern resulting in reduced SARS-CoV-2 vaccine efficacy necessitates additional prevention strategies. The structure of VLPCOV-01, a lipid nanoparticle-encapsulated, self-amplifying RNA COVID-19 vaccine with a comparable immune response to BNT162b2, was revised by incorporating a modified base, 5-methylcytosine, to reduce reactogenicity, and an updated receptor-binding domain derived from Brazil (gamma) variant. Interim analyses of a phase 1 dose-escalation booster vaccination study with the resulting construct, VLPCOV-02, in healthy, previously vaccinated Japanese individuals (N=96) are reported (jRCT2051230005). A dose-related increase in solicited local and systemic adverse events was observed, which were generally rated mild or moderate. The most commonly occurring events were tenderness, pain, fatigue, and myalgia. Serum SARS-CoV-2 immunoglobulin titers increased during the 4 weeks post-immunization. VLPCOV-02 demonstrated a favorable safety profile compared with VLPCOV-01, with a lower frequency of adverse events and fewer fever events at an equivalent dose. These findings support further study of VLPCOV-02.Competing Interest StatementM.A., D.K., N.S, S.S., J.F.S, T.S., T.F, Y.I, T.Y, and W.A conceived, designed and coordinated the study. M.A, D.K, K.K, Y.K, S.S, and N.S prepared and executed the clinical study. K.M, D.K, K.K, Y.K, M.K, A.L.M, M.A., and W.A. contributed to the data validation, analysis, writing and revision of the manuscript. All authors read and approved the manuscript, had full access to all the data in the study and had final responsibility for the decision to submit for publication.Clinical TrialjRCT2051230005Funding StatementThis study was funded by Japan Agency for Medical Research and Development (AMED), Grant No. JP21nf0101627.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of Medical Corporation Heishinkai OPHAC Hospital gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.